WallStreetZenWallStreetZen

NYSE: NVS
Novartis Ag Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NVS stock forecasts and price targets.

Forecast return on equity

Is NVS forecast to generate an efficient return?

Company
45%
Industry
-2,006.95%
Market
-53.41%
NVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVS forecast to generate an efficient return on assets?

Company
18.1%
Industry
22.79%
NVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVS earnings per share forecast

What is NVS's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$9.00+30.29%
Avg 2 year Forecast
$9.40+36.06%
Avg 3 year Forecast
$10.25+48.34%
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NVS revenue forecast

What is NVS's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$55.0B-0.32%
Avg 2 year Forecast
$56.2B+1.82%
Avg 3 year Forecast
$57.1B+3.44%
NVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVS earnings growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
13.57%
Industry
31.95%
Market
14.88%
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NVS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NVS revenue growth forecast

How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
1.16%
Industry
6.56%
Market
10.63%
NVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVS vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
NVS$126.64N/AN/A
AZN$80.19N/AN/A
MRK$85.48$94.40+10.44%Hold
AMGN$286.92$307.50+7.17%Hold
PFE$24.98$26.83+7.42%Hold
View Top General Drug Manufacturer Stocks

Novartis Ag Stock Forecast FAQ

What is NVS's earnings growth forecast for 2025-2027?

(NYSE: NVS) Novartis Ag's forecast annual earnings growth rate of 13.57% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 31.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.88%.

Novartis Ag's earnings in 2025 is $13,654,000,000.On average, 6 Wall Street analysts forecast NVS's earnings for 2025 to be $17,429,488,470, with the lowest NVS earnings forecast at $16,842,330,000, and the highest NVS earnings forecast at $17,887,716,000. On average, 6 Wall Street analysts forecast NVS's earnings for 2026 to be $18,200,751,030, with the lowest NVS earnings forecast at $16,745,535,000, and the highest NVS earnings forecast at $20,133,360,000.

In 2027, NVS is forecast to generate $19,842,975,000 in earnings, with the lowest earnings forecast at $19,513,872,000 and the highest earnings forecast at $20,288,232,000.

If you're new to stock investing, here's how to buy Novartis Ag stock.

What is NVS's revenue growth forecast for 2025-2027?

(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 1.16% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.

Novartis Ag's revenue in 2025 is $55,186,000,000.On average, 4 Wall Street analysts forecast NVS's revenue for 2025 to be $106,490,116,905,300, with the lowest NVS revenue forecast at $100,697,774,400,000, and the highest NVS revenue forecast at $112,210,571,700,000. On average, 4 Wall Street analysts forecast NVS's revenue for 2026 to be $108,782,470,300,500, with the lowest NVS revenue forecast at $102,012,250,500,000, and the highest NVS revenue forecast at $117,437,501,700,000.

In 2027, NVS is forecast to generate $110,507,831,496,000 in revenue, with the lowest revenue forecast at $105,734,986,200,000 and the highest revenue forecast at $115,124,101,200,000.

What is NVS's forecast return on assets (ROA) for 2025-2028?

(NYSE: NVS) forecast ROA is 18.1%, which is lower than the forecast US Drug Manufacturers - General industry average of 22.79%.

What is NVS's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: NVS) Novartis Ag's current Earnings Per Share (EPS) is $6.91. On average, analysts forecast that NVS's EPS will be $9.00 for 2025, with the lowest EPS forecast at $8.70, and the highest EPS forecast at $9.24. On average, analysts forecast that NVS's EPS will be $9.40 for 2026, with the lowest EPS forecast at $8.65, and the highest EPS forecast at $10.40. In 2027, NVS's EPS is forecast to hit $10.25 (min: $10.08, max: $10.48).

What is NVS's forecast return on equity (ROE) for 2025-2028?

(NYSE: NVS) forecast ROE is 45%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.